OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology M...
09 Outubro 2018 - 9:00AM
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage
biopharmaceutical company focused on discovering and developing
novel anti-cancer therapeutics, today announced that interim
results of its ongoing Phase 1b study of navicixizumab in
combination with paclitaxel in patients with platinum-resistant
ovarian cancer will be presented in a poster presentation on
October 20, 2018 at the European Society for Medical Oncology
meeting to be held in Munich, Germany.
Poster 951P/ Abstract 1389: |
A Phase 1b Study of Navicixizumab & Weekly
Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian,
Primary Peritoneal or Fallopian Tube Cancer |
|
|
Date and Time: |
Saturday, October 20, 2018 from 12:30 pm to 1:30
pm CEST |
|
|
Location: |
Hall A3 - Poster Area Networking Hub |
About Navicixizumab OncoMed's anti-DLL4/VEGF
bispecific antibody, navicixizumab, is designed to inhibit the
function of both DLL4 and VEGF and thereby induce potent anti-tumor
responses while mitigating certain angiogenic-related toxicities.
Navicixizumab was developed utilizing OncoMed's BiMAb™ bispecific
platform technology, which enables the design of bispecific
antibodies comparable to traditional monoclonal antibodies but
possessing dual target-binding specificity. In preclinical studies,
navicixizumab demonstrated robust in vivo anti-tumor efficacy
across a range of solid tumor xenografts, including colon, ovarian,
lung and pancreatic cancers, among others. Further, in preclinical
studies dual inhibition of DLL4 and VEGF appeared to exhibit
synergistic anti-tumor activity at doses where blockade of either
target alone elicited sub-optimal activity. In a Phase 1a study
with single-agent navicixizumab published in Investigational New
Drugs, 19 of 66 patients with various types of refractory solid
tumors had tumor shrinkage following treatment with navicixizumab.
Notably, 3 of the 12 (25%) ovarian cancer patients treated in the
trial achieved a partial response with single-agent navicixizumab
therapy.
About OncoMed Pharmaceuticals OncoMed
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on discovering and developing novel anti-cancer
therapeutics. OncoMed has internally discovered a broad pipeline of
investigational drugs intended to address the fundamental biology
driving cancer's growth, resistance, recurrence and metastasis.
Product candidates in OncoMed’s portfolio include navicixizumab
(anti-DLL4/VEGF bispecific, OMP-305B83), etigilimab (anti-TIGIT,
OMP-313M32), GITRL-Fc (OMP-336B11) and rosmantuzumab (anti-RSPO3,
OMP-131R10). OncoMed also continues to pursue new drug discovery
research. For further information about OncoMed Pharmaceuticals,
please see www.oncomed.com.
Forward Looking Statements To the extent that
statements contained in this press release are not descriptions of
historical facts regarding OncoMed Pharmaceuticals, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including, without limitation, OncoMed's intentions and
expectations regarding the ability of navicixizumab to induce
potent anti-tumor responses while mitigating angiogenic-related
toxicities. Such risks and uncertainties include, among others, the
uncertainties inherent in the preclinical and clinical development
process; OncoMed's ability to raise additional capital to support
the development of its unpartnered programs; and OncoMed's
dependence on its key executives. OncoMed undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to OncoMed's business in
general, see OncoMed's Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission (SEC) on March 9, 2018,
OncoMed’s Quarterly Report on Form 10-Q filed with the SEC on
August 2, 2018, and OncoMed's other current and periodic reports
filed with the SEC.
Contacts Sylvia Wheeler
sylvia.wheeler@oncomed.com |
Alexandra Santos asantos@wheelhouselsa.com |
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024